Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Permitted use of Pharma in Focus

Pharma in Focus includes both free and protected content. Free content is available to all users. Protected content is only available to registered users.

Permitted Use of Pharma in Focus protected content

  1. Pharma in Focus protected content is for the personal use of registered users only. Registered users are those who have paid a subscription for access to protected content. Protected content is any content not made available free of charge on the Pharma in Focus site or via the Pharma in Focus News Alert email.

  2. Registered users may:

    a) Access Pharma in Focus material either from their workplace computer or at home or at a remote computer if away temporarily.

    b) Make one hard copy for personal use

    c) Use the 'email a friend' facility in keeping with condition 3(a) below

  1. Registered users may not:

    a) use the 'email a friend' facility to redistribute Pharma in Focus as a whole or in any quantity or frequency which amounts to any person having substantially the benefit of unrestricted access to Pharma in Focus without having paid a subscription or having a subscription paid on their behalf

    b) use their registered email address, or permit it to be used, to allow others gain access to Pharma in Focus

    c) redistribute Pharma in Focus material to anyone by any other means.

TOP | BACK

Special Report
PBAC March outcomes in full
In a meeting that saw 22 major medicines submissions, positive and negative results were equally mixed with nine of each plus two deferrals and two no results because of a lack of data from the TGA.
Pipeline Monitor
FDA shoots down Olumiant
The FDA has surprised by rejecting Lilly and Incyte's oral rheumatoid arthritis drug Olumiant, diverging from the EU's approval of the drug in February.
Approvals Action
Keytruda wins another indication
The TGA has revealed the granting of a new indication to MSD's blockbuster cancer drug Keytruda and CSL's new product Afstyla has been approved for treating haemophilia A.